Therapeutic Asset Ratings

185 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Silymarin Cognitive Disorder	Tanta University	P2/3	CCC (55)
Sitagliptin Breast Cancer	Tanta University	P4	CCC (54)
Lactobacillus Acidophilus Parkinson Disease	Tanta University	P3	CCC (54)
Dapagliflozin Doxorubicin Induced Cardiomyopathy	Tanta University	P2	CCC (53)
Dfn-15 Parkinson Disease	Tanta University	P2	CCC (53)
Docetaxel Doxorubicin Induced Cardiotoxicity	Tanta University	P2	CCC (53)
Febuxostat Metabolic Dysfunction-Associated Steatohepatitis	Tanta University	P2	CCC (53)
Inno-206 Vitamin D Concentration	Tanta University	P2	CCC (53)
Pentoxifylline Doxorubicin Induced Cardiomyopathy	Tanta University	P2	CCC (53)
ZINC SULFATE Hepatitis B Virus Infection	Tanta University	P2	CCC (53)
ZINC SULFATE Fibrotic Liver Disease	Tanta University	P2	CCC (53)
Nitazoxanide Colorectal Cancer	Tanta University	P3	CCC (52)
Sulfasalazine Colorectal Cancer	Tanta University	P3	CCC (52)
Losartan Pancreatic Neoplasm	Tanta University	P2	CCC (52)
Allopurinol Depressive Disorder	Tanta University	P2/3	CCC (52)
Carbocysteine Metabolic Dysfunction-Associated Steatotic Liver Disease	Tanta University	P2	CCC (51)
Fexofenadine Parkinson Disease	Tanta University	P2/3	CCC (50)
Vinpocetine Parkinson Disease	Tanta University	P2/3	CCC (50)
Indocyanine Green Colon Carcinoma	Tanta University	P2	CCC (48)
Silymarin Parkinson Disease	Tanta University	P2	CCC (48)
Silymarin Breast Cancer	Tanta University	P2/3	CCC (48)
LEVAMLODIPINE Doxorubicin Induced Cardiomyopathy	Tanta University	P1/2	CC (47)
Micardis® Doxorubicin Induced Cardiomyopathy	Tanta University	P1/2	CC (47)
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril Fatty Liver Disease	Tanta University	P1/2	CC (45)
Erdosteine Fatty Liver Disease	Tanta University	P1/2	CC (45)

Showing 101 to 125 of 185 assets

PreviousPage 5 of 8Next